Publications by authors named "Mark Frasier"

Claim this Profile
C
Cognitive Performance in Early Neuronal Synuclein Disease with Hyposmia but without Motor Disability: Association with Dopamine Deficiency and Isolated Rapid Eye Movement Sleep Behavior Disorder.
Daniel Weintraub, Anuprita R Nair, Ryan Kurth, Michael C Brumm, Christine Kohnen, Mark Frasier

Ann Neurol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
Farhad Imam, Rowan Saloner, Jacob W Vogel, Varsha Krish, Gamal Abdel-Azim, Mark Frasier

Nat Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of human A53T alpha-synuclein without endogenous rat alpha-synuclein fails to elicit Parkinson's disease-related phenotypes in a novel humanized rat model.
Nicole K Polinski, Jukka Puoliväli, Leena Rauhala, Taina-Kaisa Stenius, Timo Bragge, Mark A Frasier

PLoS One· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of dopamine deficiency and REM sleep behavior disorder on cognition in early neuronal synuclein disease with hyposmia.
Daniel Weintraub, Anuprita R Nair, Ryan Kurth, Michael C Brumm, Michele K York, Mark Frasier

medRxiv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts.
Tien Dam, Gennaro Pagano, Michael C Brumm, Caroline Gochanour, Kathleen L Poston, Mark Frasier

medRxiv· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts.
Tien Dam, Gennaro Pagano, Michael C Brumm, Caroline Gochanour, Kathleen L Poston, Mark Frasier

NPJ Parkinsons Dis· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.
Tanya Simuni, Lana M Chahine, Kathleen Poston, Michael Brumm, Teresa Buracchio, Mark Frasier

Lancet Neurol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Andrew Siderowf, Luis Concha-Marambio, David-Erick Lafontant, Carly M Farris, Yihua Ma, Mark Frasier

Lancet Neurol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proteogenomic view of Parkinson's disease causality and heterogeneity.
Sergio Kaiser, Luqing Zhang, Brit Mollenhauer, Jaison Jacob, Simonne Longerich, Mark Frasier

NPJ Parkinsons Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision medicine for Parkinson's disease: The subtyping challenge.
Mark Frasier, Brian K Fiske, Todd B Sherer

Front Aging Neurosci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep Learning for Daily Monitoring of Parkinson's Disease Outside the Clinic Using Wearable Sensors.
Roozbeh Atri, Kevin Urban, Barbara Marebwa, Tanya Simuni, Caroline Tanner, Mark Frasier

Sensors (Basel)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the PREDIGT score's performance in identifying newly diagnosed Parkinson's patients without motor examination.
Juan Li, Tiago A Mestre, Brit Mollenhauer, Mark Frasier, Julianna J Tomlinson

NPJ Parkinsons Dis· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models.
Nicole K Polinski, Terina N Martinez, Sylvie Ramboz, Michael Sasner, Mark Herberth, Mark A Frasier

Dis Model Mech· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learning.
Kristen A Severson, Lana M Chahine, Luba A Smolensky, Murtaza Dhuliawala, Mark Frasier

Lancet Digit Health· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson's disease.
David W Craig, Elizabeth Hutchins, Ivo Violich, Eric Alsop, J Raphael Gibbs, Mark Frasier

Nat Aging· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in the Presentation and Progression of Parkinson's Disease by Sex.
Hirotaka Iwaki, Cornelis Blauwendraat, Hampton L Leonard, Mary B Makarious, Jonggeol J Kim, Mark Frasier

Mov Disord· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
Brit Mollenhauer, Mohammed Dakna, Niels Kruse, Douglas Galasko, Tatiana Foroud, Mark Frasier

Mov Disord· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precompetitive Consensus Building to Facilitate the Use of Digital Health Technologies to Support Parkinson Disease Drug Development through Regulatory Science.
Diane Stephenson, Robert Alexander, Varun Aggarwal, Reham Badawy, Lisa Bain, Mark Frasier

Digit Biomark· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
Lana M Chahine, Andrew Siderowf, Janel Barnes, Nicholas Seedorff, Chelsea Caspell-Garcia, Mark Frasier

J Parkinsons Dis· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Innovative Approaches for Slowing Disease Progression in Parkinson's Disease: Takeaways from the 14th Annual International Society for Central Nervous System Clinical Trials and Methodology Scientific Meeting.
Monica Javidnia, Mark Frasier, Ira Shoulson, Ibrahim Turkoz, Kumar Budur

Innov Clin Neurosci· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal analyses of cerebrospinal fluid α-Synuclein in prodromal and early Parkinson's disease.
Brit Mollenhauer, Chelsea J Caspell-Garcia, Christopher S Coffey, Peggy Taylor, Andy Singleton, Mark Frasier

Mov Disord· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI).
Neha Prakash, Chelsea Caspell-Garcia, Christopher Coffey, Andrew Siderowf, Caroline M Tanner, Mark Frasier

Parkinsonism Relat Disord· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort.
Kenneth Marek, Sohini Chowdhury, Andrew Siderowf, Shirley Lasch, Christopher S Coffey, Mark Frasier

Ann Clin Transl Neurol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Finding useful biomarkers for Parkinson's disease.
Alice S Chen-Plotkin, Roger Albin, Roy Alcalay, Debra Babcock, Vikram Bajaj, Mark Frasier

Sci Transl Med· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.
Tanya Simuni, Andrew Siderowf, Shirley Lasch, Chris S Coffey, Chelsea Caspell-Garcia, Mark Frasier

Mov Disord· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis